ClinicaliQ Trial Snapshot
- Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity — Recruiting • Non-phase study • Oncology • NCT07070765.
- What is being tested: SGLT2 inhibitors are being investigated as a potential preventive or therapeutic intervention for anthracycline-induced cardiotoxicity, a serious heart damage complication affecting approximately 10% of breast cancer patients receiving anthracycline chemotherapy.
- Patient eligibility overview: The trial focuses on breast cancer patients undergoing anthracycline treatment who are at risk of developing cardiotoxicity, with enrollment likely stratified by baseline cardiac function and cancer treatment protocols.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.
Eligibility Snapshot
- : * Patients with breast cancer between 18-70 years of age. * Patients with low to medium cardiovascular risk. * Patients scheduled for adjuvant or neo-adjuvant anthracycline therapy. * Patients who are able to give written informed consent to take part in the study. * Patients who can read and understand English. The current thresholds for defining cardiovascular risk for patients undergoing anthracycline chemotherapy are as follows: normal resting 12-lead electrocardiogram, plasma cardiac troponin I concentration < 99th centile, serum brain natriuretic peptide concentration -18% and healthy life-style (normal body-mass index, non-smoker). Low cardiovascular risk will allow for the presence of one abnormal life-style factor (body-mass index indicating obesity (>30 kg/m2), current smoker or significant smoking history), or presence of only one of the following in the clinical history: hypertension, stage 1-2 chronic kidney disease, age 65-79 years, borderline left ventricular ejection fraction (50-54%) or elevated cardiac biomarkers. Medium cardiovascular risk will permit the combination of any 2-4 of the lifestyle or clinical history variables indicated above.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.